The studys primary outcome was relative liver fat change from baseline at 24 weeks, while secondary outcomes included relative liver fat change from baseline at 48 weeks, absolute liver fat change and percent of participants achieving at least 30% liver fat reduction at weeks 24 and 48
Answer : The driving factors of the GLP-1 market are the expanding clinical indication of these therapies, which are now evolving from handling Type 2 diabetes to long-term chronic weight management and even cardiovascular risk reduction
doi:10.3389/fpsyt.2022.1092828 Tang B, Sjlander A, Wastesson JW, et al
Although she does not have diabetes or hypertension, she meets standard obesity criteria and may qualify for GLP-1 treatment if a healthcare provider determines treatment is appropriate
It is not
PubMed: 39287349 Retatrutide and Metabolic Memory: Long-term Glycemic Benefits Beyond Active Treatment human rct Knowler WC, Fowler SE, Hamman RF, et al